Chondroitin sodium sulfate – impurities and standardization problems (literature review)
https://doi.org/10.17650/1726-9784-2019-18-1-25-36
Abstract
Modern research in the field of chondroitin sulfate chemical composition is considered. Clinical efficiency and safety are shown to depend on the nature and quality of the raw material used, ways of its technological processing and the degree of purification. The composition of chemical compounds (CC) variable is stated to represent the mixture of 2 main isomeric forms: chondroitin 4-sulfate and chondroitin 6-sulfate. In the animal tissue chondroitin 4-sulfate dominates, the content of which is 70 %; the content of chondroitin 6-sulfate is 30 %. The cartilages of sharks and other hydrobionts have got low content of chondroitin 4-sulfate (10 %) and chondroitin 6-sulfate 80 %. Complex polymeric structure and instability of CC composition make the problem of drug standardization on its basis complicated. The impurities encountered in substances are considered. The impurities are divided into several groups: related impurities, technological or mechanical ones uncharacteristic of CC. Comparative analysis of requirements for raw material from the point of view of normative documentation of different countries is carried out and their considerable difference is detected. It has been shown that for raising pharmacological activity the producer of drugs must take into account all the parameters of CC including the structural composition, molecular weight and presence of impurities.
About the Authors
Е. L. Komarova
LLC “Prodekspertiza”
Russian Federation
of. 1, 8 Simferopolsky Blvd., 117149 Moscow
Russian Federation
of. 1, 8 Simferopolsky Blvd., 117149 Moscow
S. V. Chernova
Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Build. 2, 8 Trubetskaya St., 119991 Moscow
Russian Federation
Build. 2, 8 Trubetskaya St., 119991 Moscow
K. V. Kasumova
Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Build. 2, 8 Trubetskaya St., 119991 Moscow
Russian Federation
Build. 2, 8 Trubetskaya St., 119991 Moscow
M. S. Tabachnaya
Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Build. 2, 8 Trubetskaya St., 119991 Moscow
Russian Federation
Build. 2, 8 Trubetskaya St., 119991 Moscow
L. V. Оvsyannikova
Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Build. 2, 8 Trubetskaya St., 119991 Moscow
Russian Federation
Build. 2, 8 Trubetskaya St., 119991 Moscow
К. I. Eller
Federal Research Center of Nutrition and Biotechnology
Russian Federation
2/14 Ustyinsky Proezd, 109240 Moscow
Russian Federation
2/14 Ustyinsky Proezd, 109240 Moscow
References
1. Volpi N. Quality of different chondroitin sulfate preparations in relation to their therapeutic activity. J Pharm Pharmacol 2009;61(10):1271–80. DOI: 10.1211/jpp/61.10.0002. PMID: 19814858.
2. Martel-Pelletier J., Farran A., Montell E. et al. Discrepancies in composition and biological effects of different formulations of chondroitin sulfate. Molecules 2015;20(3):4277–89. DOI: 10.3390/molecules20034277. PMID: 25756648.
3. Шавловская О.А. Обзор зарубежной литературы по применению хондроитина сульфата. Русский медицинский журнал 2012;20(34):1678–82. [Shavlovskaya O.A. Foreign literature survey on chondroitin sulfate use. Russky meditsinsky zhurnal = Russian Medical Journal 2012;20(34):1678–82. (In Russ.)].
4. Хубиева А.Ю. Фармакокинетические исследования различных лекарственных форм хондроитина сульфата. Дис. ... канд. фарм. наук. М., 2007. [Hubieva A.Yu. Pharmacokinetic studies of different medical forms of chondoitin sulfate. Thesis ... of candidate of pharmaceutical sciences. Moscow, 2007. (In Russ.)].
5. Working Group on Chondroitin Sulfate. AOAC Mid-Year Meeting March 21, 2014. Maryland, USA.
6. Weiguo Z., Giancaspro G., Adams K.M. et al. Еlectrophoretic separation of alginic sodium diester and sodium hexametaphosphate in chondroitin sulfate that interfere with the cetylpyridinium chloride titration. J AOAC Int 2014;97(6):1503–13. DOI: 10.5740/jaoacint.14-167. PMID: 25372663.
7. da Cunha A.L., de Oliveira L.G., Maia L.F. et al. Pharmaceutical grade chondroitin sulfate: Structural analysis and identification of contaminants in different commercial preparations. Carbohydr Polym 2015;134:300–8. DOI: 10.1016/j.carbpol.2015.08.006. PMID: 26428128.
8. Васильев А.Н., Реутская Л.А., Байдулаева Ш.А. и др. Качество лекарственных препаратов. Суть вопроса и зарубежный опыт. Ремедиум 2014;(10):14–27. [Vasiliev A.N., Reutskaya L.A., Baidulaeva Sh.A. et al. Quality of medicinal products. The crux of the problem and foreign experience. Remedium 2014;(10);14–27. (In Russ.)]. DOI: 10.21518/1561-5936-2014-10-14-24.
9. Стейси М., Баркер С. Углеводы живых тканей. Пер. с англ. М., 1965. [Stacey M., Barker S. Carbohydrates of living tissues. Transl. from Engl. M., 1965. (In Russ.)].
10. The carbohydrates: chemistry and biochemistry. 2nd edn. Vol. IIB. Ed. by W.W. Pigman, D. Horton. Academic Press, 1970. 452 p. DOI: 10.1016/B978-0-12-556352-9. X5001-X.
11. Textbook of biochemistry with clinical correlations (6th edn.). Ed. by T.M. Devlin. Hoboken, New Jersey: Wiley‐Liss, 2006. 1208 p. DOI: 10.1002/bmb.2006.49403403236.
12. Северин Е.С. Биохимия. М.: Гэотар-Мед, 2003. 779 с. [Severin E.S. Biochemistry. Moscow: Geotar-Med, 2003. 779 p. (In Russ.)].
13. Meyer K., Linker A., Davidson E.A., Weissmann B. The mucopolysaccharides of bovine cornea. J Biol Chem 1953;205(2):611–6. PMID: 13129238.
14. Касавина Б.С., Кольчинский Т.А., Зенкевич Г.Д. Мукополисахариды костной и хрящевой ткани в норме и патологии. Успехи современной биологии 1970;69(3):353–63. [Kasavina B.S., Kolchinskiy T.A., Zenkevich G.D. The mucopoly-saccharides of bone and cartilage tissue normal and pathological. Uspekhi sovremennoy biologii = Successes of Modern Biology 1970;69(3):353–63. (In Russ.)].
15. Lindahl U., Couchman J., Kimata K., Esko J.D. Proteoglycans and sulfated glycosaminoglycans. In: Essentials of glycobiology. 3rd edn. Ed. by A. Varki et al. Cold Spring Harbor Press, 2015– 2017. DOI: 10.1101/glycobiology.3e.017.
16. Понеделькина И.Ю., Лукина Е.С., Одиноков В.Н. Кислые гликозамино-гликаны и их химическая модификация. Биоорганическая химия 2008;34(1):5–28. [Ponedelkina I.Yu., Lukina E.S., Odinokov V.N. Acid glycosaminoglycans and their chemical modification. Bioorganicheskaya khimiya = Bioorganic Chemistry 2008;34(1):5–28. (In Russ.)].
17. Хабаров В.Н., Бойков П.Я., Селянин М.А. Гиалуроновая кислота: получение, свойства, применение в биологии и медицине. М.: Практическая медицина, 2012. 224 c. [Khabarov V.N., Boykov P.Ya., Selyanin M.A. Hyaluronic acid: getting, properties, use in biology and medicine. Moscow: Practical Medicine, 2012. 224 p. (In Russ.)].
18. Funderburgh J.L. Keratan sulfate: structure, biosynthesis, and function. Glycobiology 2000;10(10):951–8. PMID: 11030741.
19. Restaino O.F., Finamore R., Diana P. et al. A multi-analytical approach to better assess the keratan sulfate contamination in animal origin chondroitin sulfate. Anal Chimica Acta 2017;958:59–70. DOI: 10.1016/j.aca.2016.12.005. PMID: 28110685.
20. Uchimura K. Keratan sulfate: biosynthesis, structures, and biological functions. Methods Mol Biol 2015;1229:389–400. DOI: 10.1007/978-1-4939-1714-3_30. PMID: 25325967.
21. Shang Q., Li Q., Zhang M. et al. Dietary keratan sulfate from shark cartilage modulates gut microbiota and increases the abundance of Lactobacillus spp. Mar Drugs 2016;14(12):224. DOI: 10.3390/md14120224. PMID: 27941632.
22. Greiling H. Structure and biological functions of keratan sulfate proteoglycans. EXS 1994;70:101–22. PMID: 8298243.
23. Rodén L., Armand G. Structure of the chondroitin 4-sulfate-protein linkage region. Isolation and characterization of the disaccharide 3-O-beta-D-glucuronosyl-D-galactose. J Biol Chem 1966;241(1):65–70. PMID: 4285135.
24. Lamari F.N., Karamanos N.K. Structure of chondroitin sulfate. Adv Pharmacol 2006;53:33–48. DOI: 10.1016/S1054-3589(05)53003-5. PMID: 17239761.
25. Шкарина Т.Н., Лутцева А.И., Ковалева С.В. и др. Лекарственные средства, содержащие хондроитин сульфат. Фармация 2007;(3):42–8. [Shkarina T.N., Lutzeva A.I., Kovaleva S.V. et al. Drugs possessing chondroitin sulfate. Farmatsiya = Farmacia 2007;(3);42–8. (In Russ.)].
26. Шкарина Т.Н. Анализ и стандартизация хондроитина сульфата натрия. Дис. ... канд. фарм. наук. М., 2009. [Shkarina T.N. Analysis and standardization of sodium sulfate chondroitin. Thesis ... of candidate of farmaceutical sciences. Moscow, 2009. (In Russ.)].
27. Seno N., Murakami K. Structure of disulfated disaccharides from chondroitin polysulfates, chondroitin sulfate D and K. Carbohydr Res 1982;103:190–4. DOI: 10.1016/S0008-6215(82)80024-4.
28. Takagaki K., Munakata H., Kakizaki I. et al. Domain structure of chondroitin sulfate E octasaccharides binding to type V collagen. J Biol Chem 2002;277(11): 8882–9. DOI: 10.1074/jbc.M106479200. PMID: 11751896.
29. Ueoka C., Nadanaka S., Seno N. et al. Structural determination of novel tetra- and hexasaccharide sequences isolated from chondroitin sulfate H(oversulfated dermatan sulfate) of hagfish notochord. Glycoconj J 1999;16(6):291–305. PMID: 10579698.
30. Kavitha G. Nadamuni G., Venkatesan C.S. et al. A pH-gradient sax-hplc method for determination of trace levels of over sulfated chondroitin sulfate and dermatan sulfate in heparin sodium. IJPSR 2014;5(11):4916–24. DOI: 10.13040/ IJPSR.0975-8232.5(11).4916-24.
31. Huckerby T.N., Nieduszynski I., Giannopoulos M. et al. Characterization of oligosaccharides from the chondroitin dermatan sulfates 1H-NMR and 13C-NMR studies of reduced trisaccharides and hexasaccharides. FEBS J 2005;272(24):6276–86. DOI: 10.1111/j.1742-4658.2005.05009.x. PMID: 16336265.
32. Fransson L.A., Rodén L. Structure of dermatan sulfate. II. Characterization of products obtained by hyaluronidase digestion of dermatan sulfate. J Biol Chem 1967;242(18):4170–5. PMID: 4228842.
33. Biology of brain dysfunction. Vol. I. Ed. by G.E. Gaull. New York/London: Plenum Press, 1973. 403 p. DOI:10.1007/978-1-4684-2667-0.
34. Shriver Z., Capila I., Venkataraman G., Sasisekharan R. Heparin and heparan sulfate: analyzing structure and microheterogeneity. Handb Exp Pharmacol 2012;(207):159–76. DOI: 10.1007/978-3-642-23056-1_8. PMID: 22566225.
35. Новиков В.Е. Хондропротекторы. Обзоры по клинической фармакологии и лекарственной терапии 2010;8(4):41–7. [Novikov V.E. Chondroprotectors. Obzory po klinicheskoy farmakologii i lekarstvennoy terapii = Reviews on Clinical Pharmacology and Drug Therapy 2010;8(4):41–7. (In Russ.)].
36. Lemaire P.A., Huang L., Zhuo Ya et al. Chondroitin sulfate promotes activation of cathepsin K. J Biol Chem 2014;289(31):21562–72. DOI: 10.1074/jbc.M114.559898. PMID: 24958728.
37. Damlar I., Esen E., Tatli U. Effects of glucosamine-chondroitin combination on synovial fluid IL-1β, IL-6, TNF-α and PGE2 levels in internal derangements of temporomandibular joint. Med Oral Patol Oral Cir Bucal 2015;20(3):е278–83. PMID: 25662545.
38. Лазебник Л.Б., Дроздов В.Н. Эффективность хондроитин сульфата при лечении гонартроза и коксартроза у больных пожилого возраста. Терапевтический архив 2005;(8):64–9. [Lazebnik L.B., Drozdov V.N. The effectiveness of chondroitin sulfate in treating gonarthrosis and coxarthrosis of elderly patients. Terapevtichesky arkhiv = Terapeutic Archive 2005;(8):64–9. (In Russ.)].
39. Ермакова И.И. Протеогликаны культуры миобластов L6J1: характеристика и влияние на адгезию, пролиферацию и дифференцировку миобластов. Дис. ... канд. фарм. наук. Санкт-Петербург, 2008. [Ermakova I.I. L6J1 Myoblast culture proteoglycans: characteristics and effects on adhesion, proliferation and differentiation of myoblasts. Thesis ... of candidate of farmaceutical sciences. St. Petersburg, 2008. (In Russ.)].
40. Сигаева Н.Н., Колесов С.В., Назаров П.В., Вильданова Р.Р. Химическая модификация гиалуроновой кислоты и ее применение в медицине. Вестник Башкирского университета 2012;17(3):1221–2. [Sigaeva N.N., Kolesov S.V., Nazarov P.V., Vildanova R.R. Chemical Modification of hyaluronic acid and its use in medicine. Vestnik Bashkirskogo universiteta = Bulletin of Bashkir University 2012;17(3):1221–2. (In Russ.)].
41. da Cunha A.L., Aguiar J.A.K., Correa da Silva F.S., Michelacci Y.M. Do chondroitin sulfates with different structures have different activities on chondrocytes and macrophages? Int J Biol Macromol 2017;103:1019–31. DOI: 10.1016/j.ijbiomac.2017.05.123. PMID: 28536017.
42. Liu S., Shen J.R., Yu R.M. Extraction and antihypertensive activity analysis of chondroitin sulfate from different animals. Zhong Yao Cai 2010;33(2):180–3. PMID: 20575407.
43. Nakazawa K., Murata K. Comparative study of the effects of chondroitin sulfate isomers on atherosclerotic subjects. Z Alternsforsch 1979;34(2):153–9. PMID: 395771.
44. Adebowale A.O., Cox D.S., Liang Z., Eddington N.D. Analysis of glucosamine and chondroitin sulfate content in marketed products and the Caco-2 permeability of chondroitin sulfate raw materials. J Am Nutrac Assoc 2000;(3):37–44.
45. Toida T., Sakai S., Akiyama H., Linhardt R.J. Immunological activity of chondroitin sulfate. Adv Pharmacol 2006;53:403–15. DOI: 10.1016/S1054-3589(05)53019-9. PMID: 17239777.
46. Volpi N. Analytical aspects of pharmaceutical grade chondroitin sulfates. J Pharm Sci 2007;96(12):3168–80. DOI: 10.1002/jps.20997. PMID: 17630645.
47. Chondroitin sulfate sodium. U.S. Pharmacopeia Monograph, USP 32–NF27:980.
48. Chondroitin sulfate sodium. European Pharmacopoeia Monographs, EP 7,0: 1681–1683.
49. Shin S.C., You S.J., An B.K., Kang C.W. Study on extraction of mucopolysaccha- ride-protein containing chondroitin sulfate from chicken keel cartilage. Asian-Australas J Anim Sci 2006;19(4):601–4. DOI: 10.5713/ajas.2006.601.
50. Srichamroen А., Nakano T., Pietrasikc Z. et al. Chondroitin sulfate extraction from broiler chicken cartilage by tissue autolysis. Food Sci Technol 2013;50(2):607–12. DOI: 10.1016/j.lwt.2012.07.039.
51. Maccari F., Galeotti F., Volpi N. Isolation and structural characterization of chondroitin sulfate from bony fishes. Carbohydr Polym 2015;129:143–7. DOI: 10.1016/j.carbpol.2015.04.059. PMID: 26050899.
52. Порцель М.Н. Разработка технологии получения хондроитин сульфата из гидробионтов Баренцева моря и изучение его физико-химических свойств. Дис. ... канд. фарм. наук. Мурманск, 2011. [Portsel M.N. Technology development of obtaining chondroitin sulfate from hydrobionts of the Barents sea and the study of its physical-chemical properties. Thesis ... of candidate of farmaceutical sciences. Murmansk, 2011. (In Russ.)].
53. Кучина Ю.А., Новиков В.Ю., Деркач С.Р. и др. Свойства хондроитина сульфата из морских гидробионтов. Х Всероссийская научная конференция и школа молодых ученых «Химия и технология растительных веществ» (Казань, 2017): тезисы докладов. Казань: ИОФХ им. А.Е. Арбузова КазНЦ РАН, 2017. C. 61–2. [Kuchina Yu.A., Novikov V.Yu., Derkach S.R. et al. Properties of chondroitin sulfate from marine hydrobionts. X All-Russian Scientific Conference and School of Young Scientists “Chemistry and Technology of Plant Substances” (Kazan, 2017): Abstracts. Kazan: IOFH them. A.E. Arbuzov KazSC RAS, 2017. Pp. 61–2. (In Russ.)].
54. Nakano T., Ikawa N., Ozimek L. An economical method to extract chondroitin sulphate-peptide from bovine nasal cartilage. Canadian Agricultural Engineering 2000;42(4):205–8.
55. Письмо No ОЗИ-578/08 от 08.09.2008 г. О контроле качества посторонних примесей в препаратах гепарина. Минздравсоцразвития РФ, Федеральная служба по надзору в сфере здравоохранения и социального развития. [Letter No. OZI-578/08 from 8.09.2008. On quality control of extraneous impurities in heparin drugs. Ministry of Health and Social Development of Russia, The Federal service frosupervision in the health and social development sphere. (In Russ.)].
56. Chess E.K., Bairstow S., Donovan S. et al. Case study: contamination of heparin with oversulfated chondroitin sulfate. Handb Exp Pharmacol 2012;(207):99–125. DOI: 10.1007/978-3-642-23056-1_6. PMID: 22566223.
57. Sakai S., Otake E., Toida T., Goda Y. Identification of the origin of chondroitin sulfate in “health foods”.Chem Pharm Bull (Tokyo) 2007;55(2):299– 303. PMID: 17268105.
58. Bertolotto A., Palmucci L., Mongini T. et al. Chondroitin, chondroitin 6-sulphate, chondroitin 4-sulphate and dermatan sulphate proteoglycans in normal and pathological human muscle. J Neurol Sci 1987;81(2–3):247–59. PMID: 3694231.
59. Worrall J.G., Wilkinson L.S., Bayliss M.T., Edwards J.C. Zonal distribution of chondroitin-4-sulphate/ dermatan sulphate and chondroitin-6-sulphate in normal and diseased human synovium. Ann Rheum Dis 1994;53(1):35–8. PMID: 8311553.
60. Pomin V.H., Piquet A.A., Pereira M.S., Mourão P.A. Residual keratan sulfate in chondroitin sulfate formulations for oral administration. Carbohydr Polym 2012;90(2):839–46. DOI: 10.1016/j. carbpol.2012.06.009. PMID: 22840010.
61. Adebowale A.O., Du J., Liang Z. at al. The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs. Biopharm Drug Dispos 2002;23(6):217–25. DOI: 10.1002/bdd.315. PMID: 12214321.
62. Concise polymeric materials encyclopedia. Ed. by J.C. Salamone. CRC Press, Technology & Engineering, 1998. 1760 p.
63. Ucakturk E., Cai C., Li L. et al. Capillary electrophoresis for total glycosaminoglycan analysis. Anal Bioanal Chem 2014;406(19):4617–26. DOI: 10.1007/s00216-014-7859-8. PMID: 24817364.
64. Vаclavíkovа E., Kvasniсka F. Quality control of chondroitin sulphate used in dietary supplements. Czech J Food Sci 2015;33:165–73. DOI: 10.17221/326/2014-CJFS.
65. Capillary electrophoresis: theory and practice. 2nd edn. Ed. by P. Camilleri. CRC Press, 1997. 576 p.
66. Ji D., Roman M., Zhou J., Hildreth J. Determination of chondroitin sulfate content in raw materials and dietary supplements by high-performance liquid chromatography with ultraviolet detection after enzymatic hydrolysis: single-laboratory validation. J AOAC Int 2007;90(3):659–69. PMID: 17580617.
Review
For citations:
Komarova Е.L., Chernova S.V., Kasumova K.V., Tabachnaya M.S., Оvsyannikova L.V., Eller К.I. Chondroitin sodium sulfate – impurities and standardization problems (literature review). Russian Journal of Biotherapy. 2019;18(1):25-36. (In Russ.) https://doi.org/10.17650/1726-9784-2019-18-1-25-36
Views:
686
Email this article 
